Zentalis Pharmaceuticals, Inc.
ZNTL
$2.76
$0.093.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -90.58% | -26.18% | -56.47% | -32.78% | 144.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.78% | -34.41% | -46.42% | -42.09% | 7.44% |
| Operating Income | 25.28% | 34.41% | 46.42% | -52.74% | 32.11% |
| Income Before Tax | 27.06% | 33.58% | 69.47% | -574.11% | 21.94% |
| Income Tax Expenses | 315.61% | -- | -- | -- | -51.85% |
| Earnings from Continuing Operations | 25.82% | 33.54% | 69.56% | -580.87% | 22.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -100.00% |
| Net Income | 25.82% | 33.54% | 69.56% | -579.53% | 22.07% |
| EBIT | 25.28% | 34.41% | 46.42% | -52.74% | 32.11% |
| EBITDA | 25.10% | 34.31% | 46.40% | -53.70% | 32.24% |
| EPS Basic | 26.23% | 34.48% | 69.96% | -574.37% | 22.55% |
| Normalized Basic EPS | 31.08% | 34.54% | 61.04% | -465.63% | 25.40% |
| EPS Diluted | 26.23% | 34.48% | 69.96% | -581.14% | 22.55% |
| Normalized Diluted EPS | 31.08% | 34.54% | 61.04% | -467.26% | 25.40% |
| Average Basic Shares Outstanding | 0.55% | 1.45% | 1.34% | 1.10% | 0.62% |
| Average Diluted Shares Outstanding | 0.55% | 1.45% | 1.34% | 0.68% | 0.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |